Amyloid Beta as a Driver of Brain Inflammaging
Current understanding
A 2026 narrative review reframes amyloid beta (Aβ) peptide as a dual-function, context-dependent contributor to brain inflammaging rather than solely an Alzheimer’s pathology marker, invoking cell-type-specific neuroinflammatory mechanisms (microglial, astrocytic, endothelial) alongside retained beneficial physiological roles and age-related failure of clearance routes [expert-opinion]. The framing positions Aβ-associated subclinical neuroinflammation as a candidate early-intervention node in age-related neurodegeneration, but the proposal is synthesis-level with no new primary data and no human intervention evidence tying Aβ-targeted anti-inflammatory strategies to clinical outcomes [expert-opinion].
Evidence log
- 2026-07-28 — Is amyloid beta peptide a driver of inflammaging?: cross-connection with atip-at2-amyloid-pathology: Both pages address amyloid pathology outside the pure AD-biomarker frame; the Aβ-inflammaging reframe complements the ATIP/AT2 signaling angle by locating Aβ in a chronic low-grade neuroinflammatory context rather than as a lesion marker. (novelty: 3)